<DOC>
	<DOCNO>NCT01140347</DOCNO>
	<brief_summary>This Phase 3 multicenter , randomize study evaluate safety efficacy ramucirumab DP plus BSC double-blind , placebo-controlled ( placebo plus BSC ) comparison . Approximately 544 participant , least 18 year age , Child-Pugh score &lt; 7 diagnosed hepatocellular carcinoma randomize . Participants must receive sorafenib first-line systemic treatment hepatocellular carcinoma ( HCC ) , must discontinue sorafenib prior enter study . Hypothesis : This sample size allow differentiation expect increase median overall survival ( OS ) , 8 month placebo arm 10.67 month ramucirumab arm . Upon registration completion screening procedure , eligible participant HCC disease progression follow first-line therapy sorafenib , intolerant agent , randomize receive either ramucirumab DP placebo . The treatment regimen continue radiographic symptomatic progression , development unacceptable toxicity , noncompliance withdrawal consent participant , investigator decision .</brief_summary>
	<brief_title>A Study Ramucirumab ( IMC-1121B ) Drug Product ( DP ) Best Supportive Care ( BSC ) Versus Placebo BSC 2nd-Line Treatment Participants With Hepatocellular Carcinoma After 1st-Line Therapy With Sorafenib</brief_title>
	<detailed_description />
	<mesh_term>Carcinoma</mesh_term>
	<mesh_term>Carcinoma , Hepatocellular</mesh_term>
	<mesh_term>Sorafenib</mesh_term>
	<mesh_term>Ramucirumab</mesh_term>
	<criteria>Inclusion criterion : Eastern Cooperative Oncology Group ( ECOG ) Performance Status ( PS ) 0 1 ChildPugh score &lt; 7 ( ChildPugh Class A ) Barcelona Clinic Liver Cancer ( BCLC ) Stage C BCLC stage B amenable locoregional therapy refractory locoregional therapy Diagnosis HCC ( exclude fibrolamellar carcinoma ) absence histologic cytologic confirmation There either clinical , laboratory , radiographic finding consistent diagnosis liver cirrhosis Has liver mass measure least 2 centimeter ( cm ) characteristic vascularization see either triphasic compute tomography ( CT ) scan magnetic resonance imaging ( MRI ) gadolinium At least 1 measurable evaluable lesion viable [ ( i.e . ) , vascularized ] , previously treat locoregional therapy . A lesion previously treat qualify measurable evaluable lesion demonstrable progression follow locoregional therapy Previously treat sorafenib discontinue sorafenib treatment least 14 day prior randomization . Participants may experience : Radiographically document disease progression sorafenib therapy discontinuation sorafenib therapy , Discontinuation sorafenib due adverse drug reaction , despite dose reduction 1 level BSC The participant receive sorafenib systemic therapeutic intervention . Any hepatic locoregional therapy administer prior sorafenib allow , follow sorafenib . Radiation metastatic site [ example ( e.g . ) , bone ] follow sorafenib therapy permit . Resolution clinically significant toxicity anticancer therapy Grade ≤1 National Cancer Institute Common Terminology Criteria Adverse Events volume 4.0 ( NCICTCAE v. 4.0 ) . Adequate Organ Function define : Total bilirubin &lt; 3.0 milligrams/deciliter ( mg/dL ) [ 51.3 micromole/liter ( µmol/L ) ] , aspartate aminotransferase ( AST ) alanine aminotransferase ( ALT ) ≤5 × upper limit normal ( ULN ) Serum creatinine ≤1.2 × ULN calculate creatinine clearance &gt; 50 milliliters/minute ( mL/min ) Absolute neutrophil count ( ANC ) ≥1.0 × 10^3/microliter ( μL ) ( 1.0 × 10^9/liter ( L ) ] ) , hemoglobin ≥9 grams/deciliter ( g/dL ) [ 5.58 millimoles/liter ( mmol/L ) ] , platelet ≥75 × 10^3/µL ( 75 × 10^9/L ) International Normalized Ratio ( INR ) ≤1.5 partial thromboplastin time ( PTT ) ≤5 second ULN . Participants receive prophylactic lowdose anticoagulant therapy eligible provide INR ≤1.5 PTT ≤5 second ULN The participant 's urinary protein ≤1+ dipstick routine urinalysis . If urine dipstick routine analysis indicate ≥2+ proteinuria , 24hour urine must collect must demonstrate &lt; 1000 milligram ( mg ) protein 24 hour allow participation study Exclusion criterion : Major surgery within 28 day prior randomization , central venous access device placement within 7 day prior randomization Hepatic locoregional therapy within 28 day prior randomization Radiation nonhepatic ( e.g. , bone ) site within 14 day prior randomization Sorafenib within 14 day prior randomization Received investigational therapy nonapproved drug within 28 day prior randomization Received previous systemic therapy vascular endothelial growth factor ( VEGF ) inhibitor vascular endothelial growth factor receptor ( VEGFR ) inhibitor ( include investigational agent ) sorafenib treatment HCC Fibrolamellar carcinoma Received transfusion , blood component preparation , erythropoietin , albumin preparation , granulocyte colonystimulating factor ( GCSF ) within 14 day prior randomization Therapeutic anticoagulation warfarin , lowmolecularweight heparin , similar agent . Participants receive prophylactic , lowdose anticoagulation therapy eligible provide coagulation parameter define inclusion criterion ( INR ≤1.5 PTT ≤5 second ULN ) meet Receiving ongoing therapy nonsteroidal antiinflammatory agent ( NSAIDs , e.g. , indomethacin , ibuprofen , naproxen , nimesulide , celecoxib , etoricoxib , similar agent ) antiplatelet agent ( e.g. , clopidogrel , ticlopidine , prasugrel , dipyridamole , picotamide , indobufen , anagrelide , triflusal ) . Aspirin ( ASA ) dose 100 milligrams/day ( mg/day ) permit Symptomatic congestive heart failure , unstable angina pectoris , symptomatic poorly control cardiac arrhythmia Any arterial thrombotic event , include myocardial infarction , unstable angina , cerebrovascular accident , transient ischemic attack , within 6 month prior randomization Uncontrolled arterial hypertension systolic ≥150 / diastolic ≥90 millimeter mercury ( mm Hg ) despite standard medical management Grade 34 gastrointestinal bleeding variceal bleed episode 3 month prior randomization require transfusion , endoscopic operative intervention ( participant bleed episode consider lifethreatening 3 month prior randomization exclude , regardless transfusion intervention status ) Esophageal gastric varix require immediate intervention ( e.g. , banding , sclerotherapy ) represent high bleeding risk . Participants evidence portal hypertension ( include splenomegaly ) prior history variceal bleeding must endoscopic evaluation within 3 month immediately prior randomization . Participants evidence portal hypertension eligible study participation endoscopic evaluation indicate esophageal gastric varix require immediate intervention represent high bleeding risk ; however , eligible participant must receive supportive therapy ( e.g. , beta blocker therapy ) accord institutional standard clinical guideline study participation Central nervous system ( CNS ) metastases carcinomatous meningitis History current hepatic encephalopathy current clinically meaningful ascites</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>November 2015</verification_date>
	<keyword>Hepatocellular carcinoma ( HCC )</keyword>
	<keyword>recombinant human immunoglobulin G</keyword>
	<keyword>subclass 1 ( IgG1 ) monoclonal antibody ( MAb )</keyword>
	<keyword>Hepatocellular Carcinoma ( HCC ) follow First-Line Therapy With Sorafenib</keyword>
</DOC>